In Brief: Novo Nordisk v. Becton Dickinson
This article was originally published in The Gray Sheet
Executive Summary
Novo Nordisk v. Becton Dickinson: Novo Nordisk files patent suit against Becton Dickinson in the U.S. District Court for the Southern District of New York. The suit alleges that BD's UltraFine II 30 gauge insulin delivery needle, a component of its BD Pen insulin delivery pen system, infringes a U.S. Novo Nordisk patent. The patent relates to Novo Nordisk's NovoFine 30 G insulin needle used in the NovoPen 1.5 insulin delivery system. The suit also alleges trademark infringement due to use of "packaging materials with false and misleading statements concerning Novo Nordisk products and trademarks." BD says it has not been served with the complaint and has not filed a response...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.